Marco LADETTO

Associate Professor

Università degli Studi del Piemonte Orientale
Country flagItaly
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

This real-world prospective observational study across 21 Italian centers ( CART-SIE ) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma with baseline characteristics matched by stabilized inverse propensity score weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs. 89.3%, P = 0.0017) and neurotoxicity (9.9% vs. 32.2%, P P = 0.0009). Even among patients who failed bridging therapy, axi-cel PFS was superior to tisa-cel (37.5% vs. 22.7%, P = 0.0059). Differences in overall survival and high-grade immune toxicities were not significant. The CAR-HEMATOTOX score not only predicted hematologic toxicity but also 1-year survival outcomes (51.5% in CAR-HEMATOTOX high vs. 77.2% in CAR-HEMATOTOX low, P Significance: The findings of this study on 485 patients with relapsed/refractory large B-cell lymphoma treated with commercial axi-cel and tisa-cel indicate axi-cel’s superior PFS after propensity score weighting. The predictive utility of CAR-HEMATOTOX in assessing not only toxicity but also outcomes across both CAR T-cell products may guide future risk-stratified management strategies.

Year:

2024

This real-world prospective observational study across 21 Italian centers ( CART-SIE ) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma with baseline characteristics matched by stabilized inverse propensity score weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs. 89.3%, P = 0.0017) and neurotoxicity (9.9% vs. 32.2%, P P = 0.0009). Even among patients who failed bridging therapy, axi-cel PFS was superior to tisa-cel (37.5% vs. 22.7%, P = 0.0059). Differences in overall survival and high-grade immune toxicities were not significant. The CAR-HEMATOTOX score not only predicted hematologic toxicity but also 1-year survival outcomes (51.5% in CAR-HEMATOTOX high vs. 77.2% in CAR-HEMATOTOX low, P Significance: The findings of this study on 485 patients with relapsed/refractory large B-cell lymphoma treated with commercial axi-cel and tisa-cel indicate axi-cel’s superior PFS after propensity score weighting. The predictive utility of CAR-HEMATOTOX in assessing not only toxicity but also outcomes across both CAR T-cell products may guide future risk-stratified management strategies.

Year:

2024

Collaborators (13)

Armando Santoro

Professore

Humanitas University

ITALY
View details

Federica Cavallo

University of Turin

ITALY
View details

Massimo Massaia

Associate Professor of Hematology

Università degli Studi di Torino

ITALY
View details

Paolo Corradini

Full Professor of Hematology

University of Milan

ITALY
View details

PIER LUIGI ZINZANI

University of Bologna

ITALY
View details

Mauro Krampera

Docenti di ruolo di Ia fascia

University of Verona

ITALY
View details

Luca Arcaini

Director of Division of Hematology

Fondazione IRCCS Policlinico San Matteo

ITALY
View details

Domenico Russo

University of Brescia

ITALY
View details

Federica Sora'

professor

Università Cattolica del Sacro Cuore

ITALY
View details

Patrizia Chiusolo

Università Cattolica del Sacro Cuore

ITALY
View details

Massimo Martino

Director Stem Cell Transplant Program

Azienda ospedaliera "Bianchi-Melacrino-Morelli"

ITALY
View details

Silva Ljevar

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

ANNALISA CHIAPPELLA

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details